Of note, the randomized phase 3 ExteNET trial, which evaluated the efficacy of neratinib treatment after neoadjuvant/adjuvant trastuzumab-based therapy, showed efficacy only in patients with estrogen receptor positive/HER2+ early-stage breast cancer [32]. This evidence concerns the gene ERBB2 and breast carcinoma.